An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy.

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2011
This article has no abstract
Epistemonikos ID: 860cbecf12f9e43ccb4f7fe7da6dddde11062df0
First added on: Jan 22, 2025